The five founders of CoreRx have developed an international reputation for being on the leading edge, in the design and implementation of novel pharmaceutical formulations for many of the world’s most renowned innovator, generic, and virtual pharmaceutical companies for more than a decade. The founders, Brian McMillan, Jim Davis, Rob Trivedi, Mark Licarde, and Dr. Todd Daviau were the core management team at their former CRO company.
CoreRx, Inc. announces new state-of-the-art website with full features for customers to request exactly what they are looking for in a proposal by using the interactive form. This newly designed website offers customers and the public a one-stop website for your pharmaceutical questions and everyday tools needed by those in the scientific fields. The website was designed by one of the top designers in the country, Holler Design.
CoreRx, Inc. announces the signing of two significant contracts in the past two weeks. These contracts involve the formulation development, analytical development and validation engineering capabilities of the CoreRx, Inc. associates. These development projects will lead into clinical manufacturing activities.
CoreRx, Inc. announces the expansion of it’s capabilities including DEA licensure for controlled substances. This gives CoreRx, Inc. the ability to work with DEA schedule 2-5 active pharmaceutical ingredients and drug products. CoreRx also announces the addition of stability storage chambers at four ICH guideline storage conditions of 4°C, 25°C/60%R.H., 30°C/65%R.H. and 40°C/75%R.H. The stability chambers will enable CoreRx, Inc. to offer both non-GMP and GMP stability study capabilities to their clients.
CoreRx™ celebrates its first year of operations August 1, 2007. In their initial year of business CoreRx™ has serviced more than 25 clients, both domestic and abroad. The company has positioned themselves for successful growth strategies over the next few years. Included in CoreRx’s™ growth strategy is the collaborative agreement between CoreRx™ and JRS Pharma, one of the world’s leading excipient manufacturers, to stabilize drug molecules using JRS’ patented PROSOLV® technology. Also, included in CoreRx’s™ growth strategy, is the company’s strict dedication to continually increase capital expenditures for equipment procurement in order to keep current and future clients on track for their respective goals and timelines. A number of clients have already returned to CoreRx™ for repeat business. One of the company’s largest clients stated, “The services provided are at a very reasonable price, coupled with superior client communication and efficient turn-around times without sacrificing the integrity or quality of work.”
CoreRx™ focuses on supporting and streamlining the drug development process for biotechnology and pharmaceutical innovators by offering services such as pre-formulation/formulation development, analytical development, clinical manufacturing and validation engineering. We have a proven track record and extensive expertise providing comprehensive drug development services to biotechnology and pharmaceutical companies worldwide.
“Our primary goal at CoreRx™ is to maintain open communications with our clients, so that we can provide innovative solutions on budget while maintaining our core values of quality, integrity, and efficiency”.
The facility is conveniently located in Tampa, Florida, a few miles from the Tampa International Airport. For more information, visit their website at www.corerxpharma.com or call (813) 514-9399.
CoreRx celebrates its first year of operations August 1, 2007. In their initial year of business CoreRx has serviced more than 25 clients, both domestic and abroad. The company has positioned themselves for successful growth strategies over the next few years. Included in CoreRx’s growth strategy is the collaborative agreement between CoreRx and JRS Pharma, one of the world’s leading excipient manufacturers, to stabilize drug molecules using JRS’ patented PROSOLV® technology.
CoreRx, Inc. was approached by News Channel 8 in Tampa FL to conduct analysis of three commonly prescribed drugs as part of an investigative study evaluating the safety and efficacy of prescription products purchased over the internet.
Clinical trial materials are already targeted and scheduled for processing in Q3, 2008. The GMP process rooms will feature a new tri-layer tablet press, high shear granulator, fluid bed dryer/granulator, bin tumbler, and co-mill. CoreRx also announces the addition of two new state of the art formulation development suites and the addition of new formulation development process equipment including laboratory fluid bed dryer/granulator, laboratory high shear granulator, laboratory tablet coater, spray dryer and various other process equipment.
Combination products provide new avenues for the development of improved drug-drug, drug-device products, as well as generating opportunities for companies to leverage their existing products & patent life. This forum will focus on the development challenges, commercial and partnering strategies, as well as the market implications of combination products.
Formulation Development firm CoreRx announces new facility which will add capacity, additional capabilities to growing laboratory in order to meet growing customer demands.
Offers students life-changing educational travel opportunities that foster friendship, build the foundation for personal success, and offer unique access to people, places, and activities.